Trial Profile

A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MYTX-011 (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms KisMET-01
Sponsors Mythic Therapeutics

Most Recent Events

31 May 2025 According to a Mythic Therapeutics media release, company presented updated data from this study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
01 May 2025 According to a Mythic Therapeutics media release, data from this trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
01 May 2025 Results presented in the Mythic Therapeutics Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com